Literature DB >> 28589775

Opportunities to significantly reduce expenditure associated with cancer drugs.

Peter J Gilbar1,2, Carole R Chambers3, Erin C Gilbar2.   

Abstract

AIM: To identify cancer drugs amenable to strategies for reducing expenditure and avoiding drug wastage.
METHODS: Information was sourced from product information in 20 countries on parenteral cytotoxic agents, and cancer and noncancer monoclonal antibodies. Data were collected on vial sizes, overage, stability and presentation forms.
RESULTS: Vial size availability varied significantly between countries, with often only single vial sizes for numerous medications. Overage was poorly reported. Stability data were inconsistent and variable between countries, with most drugs only having a 24 h expiry. Three cancer-indicated monoclonal antibodies, thought suitable for prefilled syringe administration, were only available as vials.
CONCLUSION: Many expensive cancer drugs are suitable for global cost-reduction strategies. Collaboration is vital to affecting change and reducing expenditure.

Entities:  

Keywords:  antibodies; cancer drugs; cytotoxic agents; expenditure; monoclonal; overage; stability data; vial sizes

Mesh:

Substances:

Year:  2017        PMID: 28589775     DOI: 10.2217/fon-2017-0033

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

1.  Exploratory analysis for the implementation of antineoplastic logarithmic dose banding.

Authors:  A Albert-Marí; S Valero-García; V Fornés-Ferrer; J L Poveda-Andrés
Journal:  Int J Clin Pharm       Date:  2018-08-10

2.  Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.

Authors:  Koichi Matsuo; Hisanaga Nomura; Masanobu Uchiyama; Motoyasu Miyazaki; Osamu Imakyure
Journal:  BMC Health Serv Res       Date:  2020-11-09       Impact factor: 2.655

3.  A further strategy to combat the high price of anticancer drugs.

Authors:  Peter J Gilbar
Journal:  Nat Rev Clin Oncol       Date:  2017-08-22       Impact factor: 66.675

4.  Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.

Authors:  Ya-Chen Tina Shih; Ying Xu; Hui Zhao; Deborah Schrag; James Yao
Journal:  JNCI Cancer Spectr       Date:  2021-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.